生物
背景(考古学)
PD-L1
免疫检查点
癌症
免疫系统
癌细胞
抗体
功能(生物学)
受体
配体(生物化学)
免疫
癌症研究
免疫学
免疫疗法
细胞生物学
遗传学
古生物学
作者
Chong Sun,Riccardo Mezzadra,Ton N. Schumacher
出处
期刊:Immunity
[Elsevier]
日期:2018-03-01
卷期号:48 (3): 434-452
被引量:1449
标识
DOI:10.1016/j.immuni.2018.03.014
摘要
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor immunity by counteracting T cell-activating signals. Antibody-based PD-1-PD-L1 inhibitors can induce durable tumor remissions in patients with diverse advanced cancers, and thus expression of PD-L1 on tumor cells and other cells in the tumor microenviroment is of major clinical relevance. Here we review the roles of the PD-1-PD-L1 axis in cancer, focusing on recent findings on the mechanisms that regulate PD-L1 expression at the transcriptional, posttranscriptional, and protein level. We place this knowledge in the context of observations in the clinic and discuss how it may inform the design of more precise and effective cancer immune checkpoint therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI